Pyoderma gangrenosum
Clinical trials for Pyoderma gangrenosum explained in plain language.
Never miss a new study
Get alerted when new Pyoderma gangrenosum trials appear
Sign up with your email to follow new studies for Pyoderma gangrenosum, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Matched conditions: PYODERMA GANGRENOSUM
Phase 4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a cream heal painful skin ulcers without pills?
Disease control Not yet recruitingThis phase 2 trial tests whether a topical cream containing ruxolitinib (OPZELURA) can completely heal painful ulcers in adults with pyoderma gangrenosum, a chronic inflammatory skin condition. About 12 participants will apply the cream twice daily for 24 weeks while continuing s…
Matched conditions: PYODERMA GANGRENOSUM
Phase 2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can an existing skin drug heal rare, painful wounds?
Disease control Not yet recruitingThis study tests whether bimekizumab, a drug already approved for other skin conditions, can help heal wounds in people with pyoderma gangrenosum (PG), a rare and painful skin disorder. Adults with PG will receive injections of bimekizumab every few weeks for 24 weeks. The main g…
Matched conditions: PYODERMA GANGRENOSUM
Phase 2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for painful skin ulcers: experimental drug enters human trials
Disease control Not yet recruitingThis phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the …
Matched conditions: PYODERMA GANGRENOSUM
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC